Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.6612
+0.01732.69%
Post-market: 0.6460-0.0152-2.30%19:59 EDT
Volume:3.11M
Turnover:2.03M
Market Cap:160.67M
PE:-0.88
High:0.6700
Open:0.6348
Low:0.6260
Close:0.6439
52wk High:2.54
52wk Low:0.1611
Shares:243.00M
Float Shares:196.00M
Volume Ratio:0.62
T/O Rate:1.59%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-143.17%
PB:-15.46
PE(LYR):-0.37

Loading ...

Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 16

BRIEF-Outlook Therapeutics Inc - Enters ATM Offering Agreement With H.C. Wainwright For Up To $100 Million - SEC Filing

Reuters
·
May 14

Outlook Therapeutics Inc - Enters Atm Offering Agreement With H.c. Wainwright for up to $100 Mln - SEC Filing

THOMSON REUTERS
·
May 14

Outlook Therapeutics inks $100 million at-the-market equity sales agreement with H.C. Wainwright

Reuters
·
May 14

Outlook Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
May 11

Outlook Therapeutics closes USD 5 million registered direct offering at USD 0.31/share

Reuters
·
Apr 24

Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

Dow Jones
·
Apr 24

Outlook Therapeutics to sell 16.129M shares at 31c in registered direct offering

TIPRANKS
·
Apr 22

Outlook Therapeutics prices 16,129,033-share registered direct offering at USD 0.31

Reuters
·
Apr 22

Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
Apr 22

Outlook Therapeutics Advances FDA Dispute on Wet AMD Drug

TIPRANKS
·
Apr 22

BRIEF-Outlook Therapeutics Completes Federal Dispute Resolution (Fdr) Meeting With FDA For Ons-5010/Lytenava™ (Bevacizumab-Vikg)

Reuters
·
Apr 21

Outlook Therapeutics Inc - Expects FDA Feedback in May 2026

THOMSON REUTERS
·
Apr 21

Outlook Therapeutics Files FDA Resolution Request After Rejection For Vision Loss Drug

Benzinga_recent_news
·
Apr 08

Outlook Therapeutics submits formal dispute resolution request to FDA

TIPRANKS
·
Apr 07

BUZZ-Outlook Therapeutics rises as FDA agrees to review eye drug decision

Reuters
·
Apr 07

BRIEF-Outlook Therapeutics Announces Formal Dispute Resolution Request For Ons-5010/Lytenava™ (Bevacizumab-Vikg) Accepted By FDA

Reuters
·
Apr 07

Outlook Therapeutics closes $5.0 million public offering; warrants target up to $5.0 million additional proceeds

Reuters
·
Mar 26

Press Release: Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

Dow Jones
·
Mar 26

Outlook Therapeutics Shares Drop After $5 Million Public Offering Priced

MT Newswires Live
·
Mar 25